Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Evelyn Despierre1 · Ignace Vergote1 · Ryan Anderson2 · Corneel Coens3 · Dionyssios Katsaros4 · Fred R. Hirsch2 · Bram Boeckx5,6 · Marileila Varella-Garcia7 · Annamaria Ferrero8 · Isabelle Ray-Coquard8 · John A. Green9 · Christopher Steer10 · Els M. J. J. Berns11 · Antonio Casado12 · Diether Lambrechts5,6 · Antonio Jimeno2

© Springer International Publishing Switzerland 2016

Erratum to: Targ Oncol (2015) 10:583–596
DOI 10.1007/s11523-015-0369-6

The original version of this article omitted John A. Green and Christopher Steer from the list of authors. The updated list of author names, their affiliations and an updated conflict of interest statement are shown here.

Conflict of Interest Marileila Varella-Garcia is co-inventor on a patent held by the University of Colorado to use EGFR copy number as biomarker for selection of lung cancer patients for targeted therapy. John A. Green received funding for the sample collection and coordination of the samples in the UK (NCRI) from Cancer Research UK. Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Annamaria Ferrero, Isabelle Ray-Coquard, Christopher Steer, Els MJJ Berns, Antonio Casado, Diether Lambrechts, and Antonio Jimeno declare no conflict of interest

The online version of the original article can be found at http://dx.doi.org/10.1007/s11523-015-0369-6.

✉ Evelyn Despierre
evelyn despierre@gmail.com

1 Gynecologic Oncology and Leuven Cancer Institute, and Department of Oncology, KU Leuven, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
2 University of Colorado Cancer Center, Aurora, Colorado, USA
3 EORTC Headquarters, Brussels, Belgium
4 Azienda Ospedaliera, Presidio Santa Anna, SCDO 3 Ginecologia Oncologica, Università di Torino, Turin, Italy
5 Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium
6 Vesalius Research Center (VRC), VIB, Leuven, Belgium
7 Academic Division of Gynecological Oncology, Mauriziano Hospital, Turin, Italy
8 Département d’Oncologie Médicale Adulte, Centre Leon Bérard, Lyon, France
9 Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool Clatterbridge Centre for Oncology, Bebington, Merseyside CH63 4JY, United Kingdom
10 Border Medical Oncology, 1/69 Nordsvan Drive, Wodonga, Victoria 3690, Australia
11 Erasmus MC Cancer Institute, Rotterdam, The Netherlands
12 Hospital Universitario Clínico San Carlos, Servicio de Oncología Médica, Madrid, Spain

Published online: 08 April 2016